The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
8 reports and counting
Expedition Therapeutics Raises $115M Series B for Oral DPP1 Inhibitor for COPD
Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.
Dualitas Therapeutics Appoints Karim Dabbagh Chief Executive Officer
Dualitas Therapeutics appointed Karim Dabbagh, formerly President and CEO of Silver Creek Pharmaceuticals, as Chief Executive Officer, with former interim CEO Rich Murray remaining on the Board of Directors.
Evelo Biosciences raises $75M Series D at $500M valuation
Evelo Biosciences raises $75M in Series D at $500M valuation. Monoclonal microbials for cancer and inflammation...
Celgene Ventures Headquarters - Office Location & Address
Discover Celgene Ventures's headquarters at 86 Morris Ave, Summit, NJ 07901. Investment arm of Celgene backing early-stage biotechnology and pharmaceutical companies. Focus on oncology, immunology, inflammation, and cell therapy innovations.
Amgen Inc Headquarters - Office Location & Address
Discover Amgen Inc's headquarters at 1 Amgen Center Dr, Thousand Oaks, CA 91320. Biotechnology company discovering, developing, and delivering innovative human therapeutics. Pioneer and world leader in biologics treating serious illnesses including oncology, cardiovascular, inflammation, and bone diseases.. Learn about the office facilities and work environment.
Evelo Biosciences Raises $75M in Series D
Evelo Biosciences, a Biotech company based in 620 Memorial Drive, Cambridge, MA 02139, has raised $75M in Series D at a $500M valuation led by Fidelity, Celgene, Kaiser Permanente Ventures, Flagship Pioneering.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Kinaset Therapeutics Raises $103M Series B | Inhalable JAK Inhibitor for Asthma
Biotech Kinaset Therapeutics secures $103 million Series B for inhalable pan-JAK inhibitor treating severe asthma.
Showing 8 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.